Try our Advanced Search for more refined results
Life Sciences - August, 2015
316 articles
- Patient In Genzyme Drug Suit Says Class Claims Should Stay
- Full Fed. Circ. Urged To Review Axing Of DNA Test Patent
- Sanctions Bid Accuses Novartis Unit Of Dodging Discovery
- Kyle Bass-Affiliated Group Targets Drug Patents For IPR
- CORRECTED: Skadden Guides Amicus Therapeutics' $847M Biopharm Buy
- Nexium Pay-For-Delay Plaintiffs To Appeal Loss To 1st Circ.
- Data Justified Cymbalta Risk Warnings, Eli Lilly Says
- SAC Slams Class Cert. Bid In Insider Trading Suit
- High Court Lets Ex-Va. Gov. Stay Free Amid Bribery Appeal
- Daiichi Sankyo Shells Out $8.2M In Sex Bias Settlement
- Merck Seeks Stop Of Royalty Payments For Diabetes Patents
- Nature's Way Says Ginkgo Pill Plaintiff Forgot Key Detail
- Epic Research Investors Claim CEO Lied About Credentials
- SEC Upholds Stock Suspensions Over Ebola Claims
- How Concerned Is FDA Over Cybersecurity? Look To Hospira
- Judge Keeps Gray Reed Atty Out Of Medtronic Patent Row
- 5 Insights From 3M General Counsel Ivan Fong
- Using Patents To Secure Repeat Customers
- Collecting Fees Still Tough After Octane, Highmark Cases
- Drug Cos. Win Stay Of False Ad Suit Over Painkiller Safety
- Endo Wants TCPA Suit Held Longer While FCC Mulls Fax Rule
- 2nd Circ. Won't Revive Drug Price Suit Against J&J, Others
- Merck Challenges Pa. Stormwater Permit For Vaccine HQ
- Bayer Must Face Mo. Mirena Suit After Calif. Claims Nixed
- Response Genetics Gets Nod For September Asset Sale
- Texas Court Revives $1.9M Award Over Biotech Patent Project
- Lupin, Allergan Get Support In Pay-For-Delay Fight At 1st Circ.
- Takeda Tells Jury Studies Tying Actos To Cancer Are Flawed
- The Road Ahead For Kyle Bass's IPRs
- Amarin, FDA To Discuss Settling Off-Label Promotion Dispute
- Deals Rumor Mill: Baxalta, Worldpay, Qihoo 360
- Mylan Shareholders Back Takeover As Perrigo Digs In Heels
- Fraud Claims Against Lilly Tossed In Cymbalta Labeling Row
- 5 Dos And Don'ts For Employers After NJ's Ethicon Ruling
- Takeda Hid Link Between Actos And Cancer, Nev. Jury Told
- 340B 'Mega-Guidance' Dials Back Patient Eligibility
- Stanford's Prenatal Testing Patent Appeal Moved To Fed. Circ.
- On Biosimilar Names, FDA Charts Middle Course
- Amgen Wants Biosimilar Halted For Full Fed. Circ. Review
- 7 Benefits Of Arbitration In A Patent Dispute
- Merck KGaA Sells $2.4B In Bonds To Fund Sigma-Aldrich Buy
- Merck Can't Dodge Fraud Case Over Vytorin Trials
- Greatbatch To Buy Lake Region Medical In $1.7B Deal
- 8th Circ. Nixes Jones Day's Training Video Sanction
- Tips For Responding To An FTC Subpoena
- TTAB Reverses Generic Determination For 'Skinsleeves' Mark
- Mylan Calls Apotex's Suit A Bid To Destroy Exclusivity Rights
- Chelsea Therapeutics Class Action Left Intact, With Warning
- Boston Scientific Wants Plaintiff's Murder Plea In Mesh Trial
- Janssen, Celltrion Brawl Over Fed. Circ. Biosimilar Ruling
- Bard Urges Justices To Turn Down Petition In $1B IP Dispute
- Texas Jury Acquits Cancer Agency Exec In $11M Grant Row
- Mylan Nabs AIA Review Of 2 Patents For Teva's Copaxone
- Reckitt Must Face Majority Of Mucinex Monopoly Claims
- Misrepresentation Claim Still Alive In Bayer IUD Liability Suit
- FDA Seizures Don't Negate Layoff Notice Rule: 6th Circ.
- ITC, ClearCorrect Each Say Suprema Backs Its Fed. Circ. Args
- FTC Can't Go Straight To 3rd Circ. In AbbVie Antitrust Fight
- Don't Ignore Small And Midsize Health FCA Settlements
- Unanswered Questions: China's New Pharma Advertising Rule
- PTAB Poised To Take Up Hedge Fund Hijinks In Celgene Cases
- Celgene Says High Court Ruling Limits Length Of FCA Suit
- Fed. Circ. Stands By Shire Claim Construction Ruling
- Eli Lilly Scores Win Over Teva In Alimta Patent Fight
- Plaintiffs Seek New Class Cert. In Supple False Ad Suit
- FTC Loses Reconsideration Bid In AbbVie Pay-For-Delay Suit
- FDA Warning Wire: Device Makers Feel Inspection Heat
- Eli Lilly's IP Suit Defense Based On Typo, Pharma Co. Says
- Insys Pharma Targeted By Group With Ties To Kyle Bass
- Provigil Buyers Say Drug Cos. Twisting Class Cert. Order
- Medtronic Wants Gray Reed Atty Kept Out Of Patent Row
- FDA's Focus On Drug Appearance May Cause Ugly Problems
- Ex-Va. Gov. Gets High Court Reprieve Pending Bail Issue
- Eli Lilly Blasted Over Cymbalta Labeling In Side Effect Row
- Ex-InterMune CEO's Complaints Against Trial Counsel Nixed
- Vitamin C Cos. Say No Concession In Cartel Compulsion Fight
- Medtronic Wins Dismissal Of Remaining Claims In Infuse Suit
- Stubborn FDA Invites Court Fights, Sidley Austin Atty Says
- IBM Inks $115M Boston-Area Sublease For 160K Square Feet
- Hedge Fund Manager Loses IPR Bids Against Acorda
- Medical Device Cos. Didn't Flout Patent, Texas Jury Says
- NJ Judge Axes Design Defect Claims From AlloDerm Suits
- Bankruptcy Code Doesn't Cover Pot Business, 10th Circ. Says
- Amazon Must Face Dangerous Diet Drug Suit, 2nd Circ. Told
- Walgreen, Rite Aid Slam Dismissal Bid in Opana Antitrust MDL
- Pfizer To Shed Four Products For FTC Blessing Of $17B Deal
- Supplement Co. Says 'Tainted' Judge Should Exit FTC Row
- OIG Says Certain Free Drug Starter Programs May Be OK
- FTC Renews Push For Sanctions Against Hi-Tech
- Law360 Pro Bono All Stars Show Dedication To Helping Others
- Bank Can't Collect $10M Fees From Hemispherx: 3rd Circ.
- Amgen Can't Make Journalist Testify In Shareholder Suit
- Savient Investors Lose Suit Over Pre-Bankruptcy Statements
- 20 Firms Show How To Win Big And Do Good
- Post Limelight, Could Patent Act Be More User-Friendly?
- Foreign Drug Smugglers Ordered To Pay $75M
- FTC Says Lax FDA Rules On Homeopathic Drugs Pose Conflict
- Taxation With Representation: Simpson, Shearman, Sullivan
- Judge Sides With Release Of New Covert Fetal Tissue Video
- Drug Cos. Say Loestrin Buyers Trying To Expand Actavis
- Novartis Can't Nix Gleevec Antitrust Suit, Buyers Say
- FTC Says Its Evidence Is Allowed In Robocaller Injunction Row
- The 1st IPR Institution Decisions For Biosimilars
- Amgen, Sandoz Urge Fed. Circ. To Revisit Biosimilar Ruling
- Oakland Loses 9th Circ. Fight To Keep Medical Pot Shop
- Knobbe Martens Dodges DQ Bid In Neovasc Patent Dispute
- Otsuka, Alkermes Trade Fire Over Abilify Maintena Rival
- Merck Wins Patent Dispute Over Cancer Treatment Drug
- Whistleblower Can't Depose Novartis Ex-CEO In FCA Suit
- NJ Judge Trims Sales Rep's FCA Claims In Plavix MDL
- 2 Firms Take Advantage Of Deal-Happy Life Sciences Sector
- Allergan Product-Hopping Suit Nixed On Faulty Assignments
- Pa. Appeals Court Affirms $4M Topamax Verdict
- Ex-Va. Gov. Loses Bid To Stay Free During High Court Appeal
- Purdue Agrees To NY AG's Terms On OxyContin Safeguards
- 6th Circ. Backs Class Cert. In P&G False Ad Action
- Akorn Again Hit With Fraud Suit Over Post-Merger Accounting
- Even The FDA Is Keeping Up With The Kardashians
- Valeant Inks $1B Deal For Female Libido Drugmaker Sprout
- Steris Judge Won't Question FTC's Future-Competition Theory
- Amgen Deal Struck As Tide Turns To Looser Off-Label Limits
- PTAB Won't Institute AIA Review Of Tissue Graft Patent
- Judge In FedEx Drug Case Bashes Prosecutors, Delays Trial
- Biogen Lied In Rosy Growth Forecast, Investor Suit Says
- Ex-Employee Suing Syringe Maker Apologizes For Accusations
- Ethicon Denied Retrial After $3M Bellwether Mesh Verdict
- PharMerica FCA Suit Dismissed Pending Settlement
- Ropes & Gray Settles Patent-Filing Malpractice Suit
- Top 5 Ways To Help A Law Professional Land A Job
- Bayer Can't Escape One-A-Day Labeling Class Action
- Acusphere Fights Celgene's Bid For Atty Fees In Patent Row
- How Teva Will Affect Section 337 Investigations
- Bio-Rad Investor Accuses Board Of Rampant Malfeasance
- Synergy Exec Says Nixed Launch 'Disaster' Not Tied To Merger
- FTC Calls Heath Co.'s UV-Disinfecting Claims Misleading
- Concordia, Par Settle With FTC Over Generic ADHD Drug Deal
- FDA Warning Wire: Mylan, Walgreen, MWT Materials
- 1st Female Libido Treatment Approved By FDA
- Hemispherx Can't Duck Suit Over $2.1M Exec Bonuses
- Prograf MDL Class Cert. Not Doomsday, 1st Circ. Hears
- Real Estate Rumors: Savanna, Eataly, Zoetis
- Amgen Pays $71M In Multistate Drug-Marketing Settlement
- China To Speed Up Drug, Medical Device Approval Process
- Pfizer Limited In Bid For Brualdi Firm Records, Master Says
- Allergan Nears Win Over Miotox's $600M Botox Royalty Claim
- Cherokees Want J&J Risperdal Suit Back In Okla. State Court
- FDA Puts Science Over Politics In Female Libido Pill Review
- Sen. Decries FDA's 'Reckless' Approval Of OxyContin For Kids
- Aggrenox Plaintiffs Say Boehringer's Lidoderm Take Is Wrong
- FTC Tells Court $1.9B Steris Deal Will Curb New Competition
- King & Spalding Adds Prominent Product Liability Litigator
- How Much Money Does It Take To Make A Lawyer Happy?
- Olympus Took Years To Disclose Infections, FDA Says
- Drugmaker Retrophin Sues Ex-CEO For $65M
- Ex-Pfizer Workers Tell 3rd Circ. Benefits Panel Had Conflicts
- Foley & Lardner Adds 2 K&L Gates Life Sciences Partners
- Direct Digital Asks 7th Circ. To Stay Class Cert. For High Court
- Using Social Media To Monitor Postmarket Drug Safety
- Fed. Circ. Urged To Review Toss Of Fetal DNA Test Patent
- Judge Eyes Receivership For 'Derelict' Chinese Vitamin C Cos.
- Actavis, Others Infriged Endo's Opana Patents, Judge Says
- Monopoly Claims Nixed In Solodyn Pay-For-Delay Suit
- Eli Lilly Fights Consolidation Bid For Cymbalta Suit
- FDA Guides Drugmakers On Rare Disease Research
- Texas Justices Pass On Friedman & Feiger Malpractice Row
- Gray Reed Removed From Medtronic Patent Trial In Texas
- Zimmer Expert's Model Survives Attack In Knee Implant MDL
- Merck, Sex Bias Plaintiffs Attempt To Settle Data Row
- No IPOs Ahead As August Slump Mixes With Market Volatility
- Fed. Circ. Asked Not To Revive $15M Award In Prosthetics IP
- Abbott Can't Escape Depakote Birth Defect Claims
- Mylan Fires Back As Proxy Adviser Blasts Perrigo Deal
- Boehringer Says Retailers' Aggrenox Suits Still Must Be Nixed
- Pfizer Gets Canadian Approval For $17B Hospira Takeover
- Mediation — Panacea Or Placebo?
- WuXi PharmaTech To Go Private In $3.3B Deal
- Product-Hopping Cases: A Bad Prescription For Consumers
- J&J's Herpes Test Evidence In Motrin Suit Called 'Speculative'
- Pa. Judge Narrows Class In Provigil Pay-For-Delay Suit
- AbbVie Expands Attack On FDA Biosimilar Labeling
- Deals Rumor Mill: Baxalta, TPG Capital, Femsa
- Forest Labs Jumping Gun In $100M Sex-Bias Suit, Court Told
- 2015 M&A Easily Clears $3T Mark Fueled By Megamergers
- FTC Resolves Claims Over 'Cancer-Detecting' Apps
- Ex-Teva Atty Says Changing Story Dooms Firing Defense
- J&J Units Dodge Sunscreen SPF Labeling Class Action
- J&J Wants Punitives Axed In Philly Pelvic Mesh Cases
- Hagens Berman Asks 3rd Circ. To Revive Thalidomide Suit
- NJ Appeals Court Backs Merck Victory In Vioxx Suit
- McDonnell Asks For Freedom As He Preps High Court Bid
- Judge Cuts 2nd Cymbalta Trial Short With Verdict For Lilly
- King Drug May Chill Voluntary Resolution Of IP Disputes
- Fed. Circ. Won't Rethink AIA Interference Appeals Ruling
- Sheller's Risperdal Doc Suit Against FDA Gets Tossed
- Sandoz Aims to Amend Validity Ruling In Pfizer's Toviaz Suit
- FDA Wins Toss Of Mallinckrodt Suit Over Equivalence Rating
- Abbott Hit With Birth Defect Suit Over Anti-Seizure Drug
- Life Sciences IPOs One Step Ahead Of Market Volatility
- King & Spalding Gets 4 Partners From DLA Piper
- Tax Court Says Chemist Owes $3.8M For Supplement Income
- Novartis Says Docs Request In $3.3B FCA Suit Is Too Late
- Whistleblower GC Pushes To Keep Bio-Rad In Bribery Suit
- No Kickback Penalty For Free Drugs, Inspector General Says
- AbbVie Investor Renews Push To See Books In Failed Merger
- Reckitt Hit With Suit Over Krill Oil Health Claims
- FTC's $2B Steris Merger Fight To Turn On Future Competition
- Amarin Off-Label Promotion Decision: A Watched Pot Boils
- Eli Lilly Faces Second Cymbalta Trial After Bellwether Win
- Roche Still Perfect In Accutane Appeals With Defiant Tactic
- Merck Loses At BALCA Based On Iffy Doctorate Timing
- Robbins Geller Gets $60M In $400M Pfizer Class Action Deal
- GNC Liable For Wage And Break Violations, Workers Say
- Protein Powder Co. Gets Suit Over Label, Ad Content Pruned
- FDA, Amarin Bash Watson's Bid To Join Exclusivity Fight
- Drugmakers Fight FTC Bid For Privileged Antitrust Risk Docs
- FisherBroyles Adds Practicing Physician As Partner
- Fla. Biotech Firm Settles Negligence Claims Against Attys
- FDA Warning Wire: Kim Kardashian, Valeant, Sipra
- Allergan Suit Is SLAPP Retaliation, VC Fund Contends
- 1st Circ. Asked To Uphold Class Cert. In Prograf MDL
- Pitt Sues Stem Cell Licensee Over Unpaid Royalties
- Eli Lilly Gets Expert Testimony Narrowed In Cymbalta Suit
- Fed. Circ. Mulls Suprema's Impact On ITC's Digital Authority
- ITC Overrules Novo's Objection To Baxter Expert Disclosure
- German Insurer Rips Bid To Triple Value Of Bad Blood Case
- Celgene Gets Antitrust Green Light For $7.2B Receptos Deal
- McDonnell Loses 4th Circ. Bid To Reverse Bribery Conviction
- Roche Wins Reversal Of $25M NJ Accutane Verdict
- Quality Metrics May Reduce FDA Inspections For Pharma Cos.
- FTC's Wright Urges Canada To Nix Criminal Pay-For-Delay Plan
- Amarin's Off-Label Victory Opens Door To More Injury Claims
- 3rd Circ. Axes Travelers' $22M Cephalon Drug Marketing Beef
- Tax Court Upholds $1.2M Deficiency On Marijuana Retailer
- Bayer Cipro Label Downplayed Nerve Damage Risk, Suit Says
- 4 Lessons From The FDA's Milestone Device-Hacking Alert
- Ill. Jury Sides With Zimmer In Hip Implant Defect Case
- Humana, Worker Funds Fight To Preserve Pay-For-Delay MDL
- FTC Defends Bid For Review In AbbVie Pay-For-Delay Suit
- Regeneron Hid Docs From USPTO, Judge Finds In Merus Case
- J&J Hit With Levaquin Nerve Damage Suits In Pa. State Court
- Novartis' Dementia Patch Patent Suit Gets Booted
- Suit Slams Vitamin E Maker's 'Healthy Heart' Advertising
- Wachtell Lipton Guides Mallinckrodt In $1.33B Therakos Buy
- Process Patents Are Vital In Biotech — Why Not Extend Them?
- Smith & Nephew Brings $4.5M Contract Case To Fed Court
- Ethicon Can't Shake Consolidation In Mesh Design Defect MDL
- SEC Seeks To Back Former Bio-Rad GC In Firing Suit
- Agilent Backs Request For High Court To Take $52M IP Battle
- Aetna Ordered To Allow Man's Cancer Treatment
- 5 Questions After Amarin's Off-Label Marketing Triumph
- Fed. Circ. Case Could Give ITC Power To Police Web Piracy
- Fed. Circ. Revives J&J Unit's Patent Case Against Covidien
- Eli Lilly Defeats Cymbalta Risk Claims In Bellwether Trial
- Product Liability Cases To Watch In The Second Half Of 2015
- Gibson Dunn Adds Two IP Litigators from WilmerHale
- Law Trio Aid $242M Loan For Proposed NYC Proton Facility
- 5 Cos. Set Sights On $552M As IPO Market Wavers
- Generic Pharma Co. Pushes Fed. Circ. To Revive Avanir IP Row
- Taxation With Representation: Ropes, Davis, Shearman
- Alaska Says Lupin Pay-For-Delay Probe No Fishing Expedition
- King Drug Decision May Be A Turning Point In Pay-For-Delay
- 2nd Circ. Won't Reconsider Landmark Product-Hopping Ruling
- The Circuits Clash Over Class Action Ascertainability
- Cardinal Health, Owens & Minor Win $1.2B DLA Contract Mods
- FDA's Off-Label Marketing Rules Take Hit In Amarin Fight
- Medtronic Recalls Part Of Newly Approved Heart Device
- Allergan Latest To Reveal DOJ Generic-Drug Price Probe
- 9th Circ. Sends 5 Merck Diabetes Drug Suits To State Court
- Latham Steers $160M Debut Of Allergy Biotech Aimmune
- Precision Medicine Raises More Questions Than Answers
- Ethicon Targets Plaintiff's Evidence Ahead Of Mesh Trial
- PTAB Won't Nix Drug Delivery Patent In AIA Review
- AstraZeneca Sues Chinese Co. To Block Generic Nexium
- UK Watchdog Says Pfizer Overcharged For Epilepsy Med
- Eli Lilly's Cymbalta 'Poison,' Ex-User Says In Bellwether
- Mass. Marijuana Advocates Seek Pot Legalization Vote
- Eli Lilly Says Plaintiff Doesn't Own Patent In Cialis Dispute
- Munck Wilson Adds Ex-Baker Botts Commercial Litigator
- Eli Lilly Slams Cymbalta Plaintiff Ahead Of Trial
- GSK Wants More Info On Expert For Widow Of Reed Smith Atty
- Decertification Appealed In Wellbutrin Pay-For-Delay Suit
- Iodine Product Isn't Diet Supplement, Seller Tells Court
- Pa. Judge Won't Rethink Denial Of Provigil Buyers' Class Cert.
- Takeaways From Delaware's 'New Low' In Flawed Valuation
- Lessons From 5 Years Of Public Interest Delegation At ITC
- Kirkland, Mylan Lay Down Arms In Teva Representation Fight
- Eli Lilly Hid Cymbalta Risks, Jury Told As Bellwether Opens
- Supplement Cos. Ordered To Stop Production Over Impurities
- Philly Court Proves Its Mettle Crafting Nationwide Yaz Deal
- 3rd Circ. Urged To Rethink Lamictal Pay-For-Delay Ruling
- SIGA Says It Needs Time To Keep Ch. 11 Talks On Track
- Celgene Prices $8B Note Offering To Back Receptos Deal
- FDA Warns Novartis' MS Drug Carries Risk Of Brain Infection
- TPP Sputter Brings Political Obstacles Into Focus
- Judge Slams Pretrial 'Squabbles' In $3.35B Novartis FCA Suit
- Evanston Says It Needn't Cover Fat-Burning Supplement Suit
- Class Cert. Sought In J&J 'Natural' Baby Wash False Ad Suit
- Fed. Circ. Denies Nautilus En Banc Review Of Biosig Case
- Pfizer, Zoetis Must Face Poultry Vaccine Suit In Pa.
- Fed. Circ. Affirms Allergan Win In Generic Lumigan Suit
- Bayer Agrees To $57M Deal To End Yaz Blood Clot Suits
- Overcoming Restriction Requirements On Pharma Patents
- Shire Lobs $30B Unsolicited Offer For Baxalta
- Zimmer Hit With $9.2M Verdict In Hip Implant Defect Suit
- IP Firm Denied Chance To Improve On Its Malpractice Victory
- AstraZeneca Can't Stop Mylan's Generic Nexium At Fed. Circ.
- Galderma Owes NYU's Fees For Oracea Appeal, Judge Says
- Depomed, Horizon File Competing Suits In Takeover Battle
- Lupin's Generic Colitis Drug Infringes Patents, Pharmas Say
- Feds Want Foreign Pill Smugglers Fined Nearly $50M
- Top Product Liability Verdicts In The First Half Of 2015
- AbbVie Slams FTC's Bid To Review Pay-For-Delay Ruling
- FDA Warns Hospira Pump Fails Cybersecurity Tests
- OPINION: Bipartisan Trade Secrets Legislation Is Back
- RICO Suits Challenge Off-Label Drug Marketing
- Trade Ministers Fail To Break TPP Deadlock